Role of the endocannabinoid system in depression: From preclinical to clinical evidence

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00084726" target="_blank" >RIV/00216224:14740/15:00084726 - isvavai.cz</a>
Result on the web
<a href="http://www.springer.com/us/book/9781493922932" target="_blank" >http://www.springer.com/us/book/9781493922932</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/978-1-4939-2294-9_5" target="_blank" >10.1007/978-1-4939-2294-9_5</a>

Result language
angličtina
Original language name
Role of the endocannabinoid system in depression: From preclinical to clinical evidence
Original language description
The endogenous cannabinoid system (ECS) works as pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiological conditions, which include cognitive, emotional and motivational processes. It is composedof two G protein-coupled receptors (the cannabinoid receptors types 1 and 2 [CB1 and CB2] for marijuana?s psychoactive ingredient delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and deactivation. Data from preclinical and clinical studies have reported that a hypofunction of the endocannabinoid signaling could induce a depressive-like phenotype; consequently, enhancement of endocannabinoid signaling could be a novel therapeutic avenue for the treatment of depression.
Czech name
—
Czech description
—

Project
<a href="/en/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: Central european institute of technology</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)